A uniform solution at Community level should be provided for, thereby preventing the heterogeneous development of national laws leading to further disparities which would be likely to create obstacles to the free movement of medicinal products within the Community and thus directly affect the functioning of the internal market.
Recital 7, Regulation (EC) No 469/2009 of the European Parliament and of the Council of 6 May 2009…
The 10 that are cited most themselves, of 20.
Judgment of the Court (Fourth Chamber) of 24 November 2011. Medeva BV v Comptroller General of Patents, Designs and Trade Marks.Decision
Recital 1 and recitals 4 to 10 in the preamble to Regulation No 469/2009 are worded as follows: ‘(1) Council Regulation (EEC) No 1768/92 of 18 June 1992 concerning the creation of a supplementary protection certificate for medicinal …
24 Nov 2011 · 62010CJ0322
Judgment of the Court (Fourth Chamber) of 24 November 2011. Georgetown University and Others v Comptroller General of Patents, Designs and TDecision
Recital 1 and recitals 4 to 10 in the preamble to Regulation No 469/2009 are worded as follows: Council Regulation (EEC) No 1768/92 of 18 June 1992 concerning the creation of a supplementary protection certificate for medicinal products …
24 Nov 2011 · 62010CJ0422
Judgment of the Court (Fourth Chamber), 19 July 2012. Neurim Pharmaceuticals (1991) Ltd v Comptroller-General of Patents.Decision
Recitals 1 and 4 to 10 of the SPC Regulation read as follows: Council Regulation (EEC) No 1768/92 … has been substantially amended several times. In the interests of clarity and rationality the said Regulation should be codified. ... At …
19 Jul 2012 · 62011CJ0130
Judgment of the Court (Grand Chamber) of 25 July 2018. Teva UK Ltd and Others v Gilead Sciences Inc.Decision
Recitals 3 to 5, 7, 9 and 10 of Regulation No 469/2009 state as follows: Medicinal products, especially those that are the result of long, costly research will not continue to be developed in the [Union] and in Europe unless they are …
25 Jul 2018 · 62017CJ0121
Judgment of the Court (Fourth Chamber) of 21 March 2019. Abraxis Bioscience LLC v Comptroller General of Patents.Decision
Recitals 3 to 5 and 7 to 10 of Regulation No 469/2009 state as follows: Medicinal products, especially those that are the result of long, costly research will not continue to be developed in the [European Union] and in Europe unless they …
21 Mar 2019 · 62017CJ0443
Judgment of the Court (Grand Chamber) of 9 July 2020. Santen SAS v Directeur général de l’Institut national de la propriété industrielle.Decision
Recitals 3, 4 and 7 to 10 of Regulation No 469/2009 state: Medicinal products, especially those that are the result of long, costly research will not continue to be developed in the Community and in Europe unless they are covered by …
9 Jul 2020 · 62018CJ0673
Order of the Court (Fourth Chamber) of 25 November 2011. University of Queensland and CSL Ltd v Comptroller General of Patents, Designs and Decision
Recital 1 and recitals 4 to 10 in the preamble to Regulation No 469/2009 are worded as follows: ‘(1) Council Regulation (EEC) No 1768/92 of 18 June 1992 concerning the creation of a supplementary protection certificate for medicinal …
25 Nov 2011 · 62010CO0630
Judgment of the Court (Fourth Chamber) of 30 April 2020. Royalty Pharma Collection Trust v Deutsches Patent- und Markenamt.Decision
Recitals 3 to 5, 7, 9 and 10 of Regulation No 469/2009 state as follows: Medicinal products, especially those that are the result of long, costly research, will not continue to be developed in the [European Union] and in Europe unless they …
30 Apr 2020 · 62017CJ0650
Opinion of Advocate General Saugmandsgaard Øe delivered on 13 December 2018. Abraxis Bioscience LLC v Comptroller General of Patents.Decision
According to recitals 3, 4, 5 and 9 of Regulation No 469/2009, the SPC regime has the purpose of compensating for the lack of protection conferred by a patent with respect to covering the investment put into research concerning new …
13 Dec 2018 · 62017CC0443
Judgment of the Court (Eighth Chamber) of 6 October 2015. Seattle Genetics Inc. v Österreichisches Patentamt.Decision
It should be noted in that regard that, as is apparent from recitals 7 and 8 in the preamble thereto, Regulation No 469/2009 establishes a uniform solution at European Union level by creating an SPC which may be obtained by the holder of a …
6 Oct 2015 · 62014CJ0471